Vanderbilt Breast Center at One Hundred Oaks

Clinical research site in Nashville, Tennessee

As of July 2026, 14 paid clinical trials are recruiting at Vanderbilt Breast Center at One Hundred Oaks in Nashville, Tennessee. Active studies at this site cover conditions such as Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Malignant Solid Neoplasm and Advanced Malignant Solid Neoplasm. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.

Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: July 19, 2026.

Recruiting clinical trials at Vanderbilt Breast Center at One Hundred Oaks (14)

A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer

for Breast Cancer

20 locations incl. Duarte

Sponsor: Genentech, Inc.

Sex: All·Age: 18+

Code: NCT07100106·Phase 1, Phase 2·Recruiting·Listed Aug 2025

Apply to this trial

Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer

for Advanced Endometrial Carcinoma

228 locations incl. Virginia

Sponsor: National Cancer Institute (NCI)

Sex: Female·Age: 18+

Code: NCT07198074·Phase 3·Recruiting·Listed Sep 2025

Apply to this trial

Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab

for Anatomic Stage II Breast Cancer AJCC v8

776 locations incl. Fairhope

Sponsor: Alliance for Clinical Trials in Oncology

Sex: All·Age: 18+

Code: NCT05812807·Phase 3·Recruiting·Listed Apr 2023

Apply to this trial

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

for Bladder Adenocarcinoma

224 locations incl. Phoenix

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT03866382·Phase 2·Recruiting·Listed Mar 2019

Apply to this trial

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

for Advanced Malignant Solid Neoplasm

430 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: All ages

Code: NCT05564377·Phase 2·Recruiting·Listed Oct 2022

Apply to this trial

E-Mindfulness Approaches for Living After Breast Cancer

for Breast Cancer

357 locations incl. Phoenix

Sponsor: NRG Oncology

Sex: All·Age: 18 - 50

Code: NCT06748222·Phase 3·Recruiting·Listed Dec 2024

Apply to this trial

Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer

for Refractory Differentiated Thyroid Gland Carcinoma

288 locations incl. Anchorage

Sponsor: ECOG-ACRIN Cancer Research Group

Sex: All·Age: 18+

Code: NCT06475989·Phase 3·Recruiting·Listed Jun 2024

Apply to this trial

Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain

for Anatomic Stage IV Breast Cancer AJCC v8

257 locations incl. Tucson

Sponsor: NRG Oncology

Sex: All·Age: 18+

Code: NCT06500455·Phase 3·Recruiting·Listed Jul 2024

Apply to this trial

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study

for Muscle Invasive Bladder Urothelial Carcinoma

208 locations incl. Fort Smith

Sponsor: NRG Oncology

Sex: All·Age: 18+

Code: NCT07097142·Phase 3·Recruiting·Listed Jul 2025

Apply to this trial

De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)

for Stage I Breast Cancer

707 locations incl. Mobile

Sponsor: NRG Oncology

Sex: All·Age: 50 - 70

Code: NCT04852887·Phase 3·Recruiting·Listed Apr 2021

Apply to this trial

Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer

for Fallopian Tube Endometrioid Adenocarcinoma

645 locations incl. Birmingham

Sponsor: NRG Oncology

Sex: All·Age: 18+

Code: NCT06580314·Phase 3·Recruiting·Listed Aug 2024

Apply to this trial

A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer

for Ovarian Carcinoma

473 locations incl. Birmingham

Sponsor: NRG Oncology

Sex: Female·Age: 35 - 50

Code: NCT04251052·Recruiting·Listed Jan 2020

Apply to this trial

Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)

for Advanced Malignant Solid Neoplasm

27 locations incl. Duarte

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT06311214·Phase 2·Recruiting·Listed Mar 2024

Apply to this trial

Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer

for Anatomic Stage III Breast Cancer AJCC v8

6 locations incl. Boston

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT05422794·Phase 1·Recruiting·Listed Jun 2022

Apply to this trial

More research sites in Nashville

Vanderbilt University Medical Center (369 trials)
SCRI Oncology Partners (127 trials)
Vanderbilt University/Ingram Cancer Center (86 trials)
Sarah Cannon Research Institute (62 trials)
Vanderbilt University (55 trials)
Tennessee Oncology (48 trials)
Vanderbilt-Ingram Cancer Center (39 trials)
The Children's Hospital at TriStar Centennial (28 trials)
Monroe Carell Jr. Children's Hospital at Vanderbilt (13 trials)
Tennessee Oncology, PLLC (13 trials)

Explore more

Paid clinical trials in Nashville, TN · Tennessee clinical trials